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Abstract
Interleukin-6 (IL-6) is a pleiotropic cytokine with pivotal functions in the regulation of the biological
responses of several target cells including hepatocytes. The level of serum IL-6 has been reported
to be elevated in patients with chronic hepatitis B, cirrhosis and hepatocellular carcinoma and
represents the best marker of HBV-related clinical progression as compared with several other
cytokines. In this study, we found that IL-6 was able to effectively suppress hepatitis B virus (HBV)
replication and prevent the accumulation of HBV covalently closed circular DNA (cccDNA) in a
human hepatoma cell line. We also demonstrated that the suppression of HBV replication by IL-6
requires concurrently a moderate reduction of viral transcripts/core proteins and a marked
decrease in viral genome-containing nucleocapsids. Studies on the stability of existing viral capsids
suggest that the IL-6 effect on the reduction of genome-containing nucleocapsids is mediated
through the prevention of the formation of genome-containing nucleocapsids, which is similar to
the effect of interferons. However, IFN-/ and IFN- did not participate in the IL-6-induced
suppression of HBV replication. Taken together, our results will provide important information to
better understand the role of IL-6 in the course of HBV infection.
Background
Hepatitis B virus (HBV) is a hepatotropic, non-cytopathic
DNA virus (3.2 kb partially double-stranded DNA) that
causes acute and chronic hepatitis. More than 350 million
people worldwide suffer from chronic hepatitis B (CHB)
infection, which is associated with a high risk of develop-
ing cirrhosis and hepatocellular carcinoma [1,2]. The
interactions between HBV replication and immune
responses against HBV infection play an important role in
determining the outcome of virus infection [3,4]. Previous
studies using chimpanzees and transgenic mice models
have indicated that HBV clearance occurs prior to the
destruction of infected cells [5,6]. These results suggest
that cytokines are likely to be involved in both the regula-
tion of the immune responses and the direct inhibition of
HBV replication. Several cytokines have recently been
shown to effectively suppress HBV replication in a noncy-
topathic manner in HBV transgenic mice and in a cell cul-
Published: 20 April 2009
Journal of Biomedical Science 2009, 16:41 doi:10.1186/1423-0127-16-41
Received: 16 February 2009
Accepted: 20 April 2009
This article is available from: http://www.jbiomedsci.com/content/16/1/41
© 2009 Kuo et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Biomedical Science 2009, 16:41 http://www.jbiomedsci.com/content/16/1/41
Page 2 of 9
(page number not for citation purposes)
ture system. Interleukin-12 (IL-12), IL-18 and intrahepatic
induction of alpha/beta interferon (IFN-/) are able to
effectively inhibit HBV replication in the liver of trans-
genic mice [7-9]. IFN-/, gamma interferon (IFN-) and
tumor necrosis factor alpha (TNF-) suppress HBV repli-
cation in immortalized murine hepatocytes and human
hepatoma cells by preventing the formation of viral cap-
sids or disrupting capsid integrity [10,11]. Furthermore,
IL-4 and transforming growth factor beta-1 (TGF-1) have
been demonstrated to suppress HBV replication in
hepatoma cells through the transcriptional regulation of
HBV RNA [12,13]. These studies suggest that inflamma-
tory cytokines play an important role in the antiviral
response against HBV infection.
IL-6 is one of the major inflammatory cytokines, and in
several types of target cells it affects a variety of biological
responses including changes in cell differentiation,
growth, apoptosis and the induction of acute-phase
responses [14,15]. In response to liver injury, IL-6 expres-
sion is induced in various cell types including endothelial
cells, hepatocytes and Kupffer cells [16]. IL-6 plays an
important role in promoting hepatic survival by stimulat-
ing liver regeneration, and protects the liver from damage
caused by immune responses, alcohol and viral infection.
The level of serum IL-6 has been reported to be elevated in
patients with CHB, cirrhosis and hepatocellular carci-
noma, relative to normal subjects [17-19]. IL-6 activity
has been shown to be significantly enhanced during acute
exacerbation of CHB, which is accompanied by clearance
of HBV e antigen (HBeAg). Interestingly, the level of
serum IL-6 were reported to be inversely correlated to the
transaminase level in patients and represents the best
marker of HBV-related clinical progression as compared
with IL-10, IL-12 and IFN- [20]. Recent experiments have
also indicated that gender may influence MyD88-depend-
ent IL-6 production by Kupffer cells, and this may contrib-
ute to gender disparity in hepatocarcinogenesis [21].
Using a human-mouse radiation chimera model, Galun et
al. found that IL-6 could facilitate HBV infection and sug-
gested that IL-6 might be a potential mediator for HBV
entrance into hepatocytes [22]. However, the effect and
the mechanisms of action of IL-6 on HBV replication have
not been studied in detail.
In this study, we found that IL-6 can effectively suppress
HBV replication in an HBV-producing cell line, 1.3ES2
[23]. The suppression of HBV replication requires a mod-
erate reduction of viral transcripts/core proteins and a
marked decrease in the formation of HBV genome-con-
taining nucleocapsids. Our studies provide important
information to reveal the role of IL-6 in the course of HBV
infection.
Materials and methods
Cell culture
HepG2 and 1.3ES2 cells were maintained in Dulbecco's
modified Eagle's medium (DMEM) containing 10% fetal
calf serum, as described previously [23]. After culture for
4 days, the confluent 1.3ES2 cells were serum-deprived for
2 days and treated with human IL-6 (R&D Systems Inc.,
Minneapolis, USA) for various periods to assess the anti-
viral effect of IL-6. The culture medium was refreshed
every 2 days during the experiments. For the neutraliza-
tion experiment, sheep polyclonal anti-IFN- antibody
(PBL Biomedical Laboratories, New Jersey, USA) was
added to the culture medium to block the endogenous
IFN- activity. Human IFN- (PBL Biomedical Laborato-
ries, New Jersey, USA) was added as a control for the neu-
tralization experiment.
Southern blot analysis
Total DNA (20 g) was digested with HindIII and sepa-
rated on 0.7% agarose gels. The gels were treated as
described previously [23] and the DNA samples were
transferred onto nylon membranes (Amersham, Freiburg,
Germany). After ultraviolet crosslinking and prehybridi-
zation, the membranes were hybridized with an HBV-spe-
cific probe generated using a random-primed labeling kit
(Amersham, Freiburg, Germany).
Analysis of intracellular HBV genome-containing 
nucleocapsid
Analysis of intracellular HBV genome-containing nucleo-
capsids was performed as described previously [13,24].
Briefly, cell lysates were separated using a 0.8% native aga-
rose gel and transferred onto nylon membranes. Capsid-
associated nucleic acids were released from the nucleocap-
sids in situ by denaturing with 0.2 N NaOH/1.5 M NaCl
followed by neutralization with 0.2 N Tris-HCl/1.5 M
NaCl. The membranes were then hybridized with an HBV-
specific probe.
Northern blot analysis
Total RNA was isolated using TRIzol solution (Invitrogen,
California, USA) according to the manufacturer's instruc-
tions, and 15 g of isolated RNA was separated using a
1.2% formaldehyde-agarose gel and transferred onto
nylon membrane. The membranes were then hybridized
with an HBV-specific probe.
Western blot analysis
Total protein (100 g) was separated using a 15% SDS-
polyacrylamide gel and then transferred onto polyvinyli-
dene fluoride membranes (Millipore, Massachusette,
USA). The membranes were incubated with anti-core anti-
body (DakoCytomation, Glostrup, Denmark) or anti-
actin antibody (Sigma, St. Louis, MO). The immunoblotJournal of Biomedical Science 2009, 16:41 http://www.jbiomedsci.com/content/16/1/41
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signals were examined using enhanced chemilumines-
cence reagent (Millipore, Massachusette, USA).
Analysis of extracellular HBV nucleic acids
The extracellular pool of HBV nucleic acids was extracted
from cell culture medium using a High Pure Nucleic Acid
Kit (Roche Applied Science, Mannheim, Germany). The
level of viral genomes was then measured by real-time
PCR method using a LightCycler® TaqMan® Master Kit
(Roche Applied Science, Mannheim, Germany) with a
pair of HBV-specific primer (forward primer: 5'-GCTC-
CAGTTCAGGAACAGTAAAC-3' and reverse primer: 5'-
AATCCTCGAGAAGATTGACGAT-3') and the Taqman
probe #34. The thermo-cycling parameters were 94°C for
10 min; 50 cycles of 94°C for 10 sec, 60°C for 30 sec, and
72°C for 1 min; and 40°C for 30 sec.
Detection of HBsAg and HBeAg
The levels of HBV surface antigen (HBsAg) and HBeAg in
the culture medium were assessed using an enzyme-
linked immunosorbent assay (ELISA) following the man-
ufacturer's protocol (Evernew Biotech Inc, Taipei, Tai-
wan). Each experiment was performed in triplicate and
independently repeated three times.
Nucleocapsid stability
Confluent 1.3ES2 cells were labeled with [35S] methio-
nine-cysteine protein labeling mix (Perkin-Elmer, Con-
necticut, USA) for 6 h and then chased by replacing with
unlabeled medium in the absence or presence of IL-6 (20
ng/ml or 40 ng/ml) for 24 h or 48 h. Cell lysates were har-
vested and the nucleocapsids were separated from free
core protein by centrifugation through a Centricon-100
filter with a retention cutoff of 100 kDa (Millipore, Mas-
sachusette, USA). Total core proteins and nucleocapsids
were then immunoprecipitated using an anti-core anti-
body and separated by 12% SDS-polyacrylamide gel elec-
trophoresis. The signal of labeled core protein was
visualized by autoradiography.
Hirt extraction
HBV cccDNAs were isolated as previously described [23].
After complete lysis of the cells with Hirt solution, 750 l
of 5 N NaCl was added to the cell lysate and the mixture
incubated on ice overnight. The supernatant was collected
after centrifugation and extracted with phenol/chloro-
form. HBV cccDNA was then precipitated by ethanol and
examined by Southern blot analysis.
Primer pairs for RT-PCR
The cDNA templates were amplified by the following
primer pairs: (1) IFN-2b forward primer: 5'-TCCTA-
GACAAATTCTACACTGAAC-3', IFN-2b reverse primer:
5'-GCTCTGACAACCTCCC-3'. (2) IFN- forward primer:
5'-AAACTCATGAGCAGTCTGCA-3', IFN- reverse primer:
5'-AGGAGATCTTCAGTTTCGGAGG-3'. (3) IFN- forward
primer: 5'-TCAGCTCTGCATCGTTTTGG-3', IFN- reverse
primer: 5'-GTTCCATTATCCGCTACATCTGAA-3'. (4) -
actin forward primer: 5'-TGAACTGGCTGACTGCTGTG-
3',  -actin reverse primer: 5'-CATCCTTGGCCTCAG-
CATAG-3'. (5) GBP-1 forward primer: 5'-ACAAG-
GGAACAGCCTGGACATGG-3', GBP-1 reverse primer: 5'-
GCCCACAATTGCCACCACCA-3'. (6) MxA forward
primer: 5'-ACCACAGAGGCTCTCAGCAT-3', MxA reverse
primer: 5'-CTCAGCTGGTCCTGGATCTC-3'. (7) GAPDH
forward primer: 5'-GCTGAGAACGGGAAGC-3', GAPDH
reverse primer: 5'-GGTGAAGACGCCAGTG-3'.
Results
IL-6 suppressed HBV replication in the HBV-producing cell 
line 1.3ES2
To evaluate the effect of IL-6 on HBV replication, an HBV-
producing cell line (1.3ES2) was established by stably
transfecting HepG2 cells with 1.3-fold HBV genome [23].
The 1.3ES2 cells were chosen because of their abundant
expression of viral replicative intermediates and the
capacity to support the formation of covalently closed cir-
cular DNA (cccDNA). To determine the dose of IL-6 that
effectively interfered with HBV replication, confluent
1.3ES2 cells (day 6 after plating) were treated with various
concentrations of IL-6 under serum-starvation conditions.
For the detection of intracellular HBV genome-containing
nucleocapsids, cell lysates were separated by native agar-
ose gel electrophoresis and performed by particle blot
analysis. The viral genome-containing nucleocapsids were
detected with an HBV-specific probe. After treatment for 4
days, IL-6 reduced HBV genome-containing nucleocap-
sids in a dose-dependent manner, with significant sup-
pression effect observed at a concentration of 5 ng/ml
(Fig. 1A). At 20 ng/ml of IL-6, a marked reduction
(79.4%) of genome-containing nucleocapsids was evi-
dent as compared with the mock control. The effect of IL-
6 on the proliferation of 1.3ES2 cells was also examined.
The results indicated that growth of 1.3ES2 cells under
serum-starvation increased in a dose-dependent manner
after 4 days of treatment (Fig. 1B). There was no obvious
apoptotic cell death in either the IL-6-treated or the con-
trol groups (data not shown). These results indicate that
although IL-6 slightly increased 1.3ES2 cell proliferation,
it could effectively inhibit HBV replication in a noncyto-
pathical manner.
To investigate the kinetics of IL-6 on suppression of HBV
replication, confluent cells (indicated as day 0) were
treated with 20 ng/ml of IL-6, and total cellular DNA was
extracted at day 2, day 4 and day 6. The levels of HBV rep-
licative intermediates increased with time in the control
cells, but decreased dramatically in the IL-6-treated cells
(Fig. 2). At day 2, the level of DNA replicative intermedi-
ates in IL-6-treated cells was reduced to 59.7% of the con-Journal of Biomedical Science 2009, 16:41 http://www.jbiomedsci.com/content/16/1/41
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IL-6 suppresses HBV replication in a dose-dependent manner Figure 1
IL-6 suppresses HBV replication in a dose-dependent 
manner. (A) 1.3ES2 cells were treated 6 days after plating 
(when the cells had reached confluence) with various doses 
of IL-6 (0, 5, 10, 20, 40 ng/ml). The cell lysates were har-
vested after 4 days treatment with IL-6 and equal amounts of 
sample were analyzed by particle blot analysis using native 
agarose gel electrophoresis. HBV genome-containing nucleo-
capsids were detected by Southern blot analysis of the dis-
rupted nucleocapsids, using an HBV-specific probe. 
Expression of -actin was used as an internal control for sam-
ple loading. The signals were quantified by densitometry anal-
ysis and expressed as percentage of the control cells to 
indicate the inhibitory effect of IL-6. (B) Effect of IL-6 on 
growth curve. The cells were treated with IL-6, as described 
above. The cell number was determined by the trypan blue 
exclusion method.
trol cells, at day 4 was reduced to 25.6%, and at day 6 was
reduced to 13.6%. These results indicate that HBV replica-
tion was significantly suppressed by IL-6 treatment in a
time-dependent manner.
IL-6 suppressed HBV replication through moderate 
reduction of viral transcripts and marked decrease in the 
genome-containing nucleocapsid levels
To further characterize the mechanisms involved in the
antiviral effect of IL-6, the levels of viral transcripts, core
protein and genome-containing nucleocapsids were
simultaneously examined with or without IL-6 treatment
in three independent experiments. A representative exper-
iment and the statistical analyses are given in Fig. 3. After
IL-6 treatment, the HBV transcripts and core protein were
moderately reduced (Fig. 3, panels for RNA and proteins).
At day 2 and day 4 the levels of HBV RNAs were reduced
in IL-6 treated cells to 73 ± 10% and 75 ± 3% as compared
with the control cells, and at day 6 was reduced to 68 ±
6%. Similarily, the levels of core protein were also reduced
by IL-6. At day 2, day 4 and day 6, the levels of core pro-
tein were reduced to 79 ± 6%, 83 ± 5% and 78 ± 2% as
compared with the control cells. Interestingly, the
genome-containing nucleocapsids were decreased to
more significant levels after IL-6 treatment (Fig. 3, panel
for genome-containing nucleocapsids). At day 2, the level
of genome-containing nucleocapsids was reduced in IL-6
treated cells to 60 ± 3% of control cells, at day 4 was
reduced to 43 ± 10% and at day 6 was reduced to 27 ± 6%.
The reduction in levels of HBV genome-containing nucle-
ocapsids was compared to that of core proteins and the
differences were highly significant (p = 0.03, 0.00 and
0.01 at day 2, 4 and 6 respectively). These results clearly
indicated that the dramatically inhibitory effect on HBV
genome-containing nucleocapsids can not be explained
only by the moderate reduction of HBV transcripts and
core proteins. It is likely that the dramatic reduction of
IL-6 suppresses HBV replication in a time-dependent manner Figure 2
IL-6 suppresses HBV replication in a time-dependent 
manner. Confluent cells (day0) were treated with or with-
out 20 ng/ml of IL-6 for 2 days (day2), 4 days (day4) or 6 days 
(day6). For the analysis of HBV replicative intermediates, 
equal amounts of total DNA were subjected to HindIII diges-
tion and separated by electrophoresis. The integrated viral 
genome and viral replicative intermediates were then exam-
ined by Southern blot analysis using an HBV-specific probe. 
Bands corresponding to the integrated genome, the relaxed 
circular double-stranded DNA (RC) and single-stranded 
DNA (SS) are indicated individually. The intensity of the inte-
grated HBV genome in each lane reflected the amounts of 
total DNA and was served as the internal control for sample 
loading. The signals were quantified by densitometry analysis 
and expressed as percentage of the respective control cells 
to indicate the inhibitory effect of IL-6.Journal of Biomedical Science 2009, 16:41 http://www.jbiomedsci.com/content/16/1/41
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Figure 3
IL-6 decreases the levels of HBV transcripts, core
protein, and genome-containing nucleocapsids. Con-
fluent cells (day0) were treated with or without 20 ng/ml of
IL-6 for 2 days (day2), 4 days (day4) or 6 days (day6). For
RNA analysis (panel for RNA), total RNAs were extracted
and equal amounts of samples were subjected to Northern
blot analysis to reveal the expression profile of the HBV tran-
scripts, namely those of 3.5-kb and 2.4-kb/2.1-kb respectively.
The expression level of 18S rRNA was used as an internal
control for sample loading. For Western blot analysis (panel
for Proteins), cell lysates were harvested and equal amounts
of samples were separated by SDS-polyacrylamide gel elec-
trophoresis. The total core protein was subsequently
detected by immunoblot analysis with antibodies against core
protein. The expression level of -actin was used as an inter-
nal control for sample loading. For particle blot analysis, equal
amounts of cell lysates were assayed for viral capsid by native
agarose gel electrophoresis. HBV genome-containing nucleo-
capsids were then detected by Southern blot analysis of the
disrupted nucleocapsids using an HBV-specific probe (panel
for Genome-containing nucleocapsids). The signals including
3.5-kb RNA, core proteins and genome-containing nucleo-
capsids were quantified by densitometry analysis and
expressed as the average percentage of respective control
cells from three independent experiments to indicate the
inhibitory effect of IL-6. Results shown are representative of
three independent experiments. *: The reduction in levels of
HBV genome-containing nucleocapsids was compared with
that of core proteins and found to be highly significant (P <
0.05 as monitored by Pearson 2 test).
IL-6 does not suppress the levels of secreted HBeAg and  HBsAg Figure 4
IL-6 does not suppress the levels of secreted HBeAg 
and HBsAg. Confluent cells were treated for 6 days with 
various doses of IL-6 (0, 5, 10, 20, 40 ng/ml). (A) The level of 
extracellular viral genome-containing nucleocapsids in the cul-
ture medium was measured by real-time PCR method and 
normalized with total cell number. (B and C) The levels of 
secreted HBeAg and HBsAg in the culture medium were 
measured by ELISA. Results shown are representative of 
three independent experiments.Journal of Biomedical Science 2009, 16:41 http://www.jbiomedsci.com/content/16/1/41
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genome-containing nucleocapsids also involves the dis-
ruption of existing capsids, which is similar to the effect of
TNF- [11], or interference with the assembly of genome-
containing nucleocapsids as interferons [10].
To assess whether IL-6 could also affect the extracellular
pool of viral genome-containing nucleocapsids in the cul-
ture medium, the level of secreted viral genome in the
presence of different concentrations of IL-6 was estimated
by real-time PCR method. As shown in Figure 4A, the level
of viral genomes was dramatically decreased with IL-6
treatment for 6 days in a dose-dependent manner with
significant reduction observed at 5 ng/ml. At 20 ng/ml of
IL-6, a marked reduction (39.8%) of genome-containing
nucleocapsids was evident as compared with the mock
control. However, the quantities of secreted HBeAg and
HBsAg in the culture medium were not decreased by IL-6
treatment as measured by ELISA analysis (Fig. 4B and 4C).
Taken together, these results imply that IL-6 exerts its anti-
viral activity through combinational effects which include
a moderate reduction of HBV transcripts/core proteins
and a marked decrease in HBV genome-containing nucle-
ocapsids.
IL-6 did not disrupt the HBV nucleocapsids
To understand whether the disruption of existing nucleo-
capsids is involved in the suppression of HBV replication,
1.3ES2 cells were labeled with [35S] methionine-cysteine
for 6 h and treated with IL-6 for 24 h or 48 h. Following
lysis, total cell lysates were collected. The intact core parti-
cles were collected by centrifugation through centricone
filter with cutoff of 100 kDa as reported previously [11].
The total lysate and the intact core particles were then
immunoprecipitated with anti-core antibody. As shown
in Fig. 5, there was no appreciable change in the levels of
total HBV core proteins or viral capsids after 24 h or 48 h
treatment with 20 ng/ml or 40 ng/ml of IL-6. Taken
together, these results indicated that the antiviral effect of
IL-6 is not due to the disruption of capsid integrity as the
TNF- [11]. On the other hand, our results suggest that IL-
6 may prevent the formation of genome-containing nucle-
ocapsids similar to interferons [10]).
The antiviral effect of IL-6 was not mediated through 
induction of interferons
IFN-/ and IFN- have been reported to noncytopathi-
cally suppress HBV replication through the prevention of
HBV genome-containing nucleocapsids production in cell
culture systems [10]. To assess whether interferons were
involved in the antiviral effect of IL-6 on HBV replication,
the induction of IFN-/ and IFN- was measured in the
1.3ES2 cells after IL-6 treatment. Using RT-PCR analysis,
we found that the expression of IFN-2b, IFN- and IFN-
 was not induced after 6 days of treatment with IL-6 (Fig.
6A). Similarly, the expression of MxA (the target gene for
type I IFN) and GBP-1 (the target gene for IFN-) was not
induced under the same condition (Fig. 6B). Furthermore,
anti-IFN- polyclonal antibody was added to the culture
medium to block the endogenous IFN activity and exam-
ine its effect on the suppression of HBV replication
induced by IL-6. As shown in Fig. 6C, the suppressive
effect of IL-6 on the level of HBV genome-containing
nucleocapsids was not affected by the presence of anti-
IFN- antibody. On the other hand, IFN--mediated anti-
viral effect was blocked by the anti-IFN- antibody. In
conclusion, our results clearly indicated that IFN-/ and
IFN- did not participate in the IL-6-induced suppression
of HBV replication
IL-6 prevents the accumulation of HBV cccDNA
HBV cccDNA plays a pivotal role in the life cycle of HBV
replication and maintenance of HBV persistent infection.
The observation that IL-6 effectively decreased the level of
HBV replicative intermediates raised the possibility that
IL-6 might also affect the formation of HBV cccDNA. To
examine the IL-6 effect on the amount of cccDNA, viral
nucleic acid was prepared by Hirt extraction after 4 days or
6 days treatment with or without IL-6. The replicative
intermediates including relax-circular and duplex-linear
IL-6 does not disrupt the HBV nucleocapsids Figure 5
IL-6 does not disrupt the HBV nucleocapsids. To 
assess the IL-6 effect on the stability of HBV nucleocapsids, 
confluent cells were labeled with [35S] methionine-cysteine 
protein labeling mix for 6 h and then chased in the absence 
or presence of IL-6 (20 ng/ml or 40 ng/ml) for 24 h or 48 h. 
Cell lysates were harvested and the nucleocapsids were sep-
arated from free core protein by centrifugation through a 
Centricon-100 filter with a retention cutoff of 100 kDa. Total 
core protein and nucleocapsids were then immunoprecipi-
tated using an anti-core antibody and separated by SDS-poly-
acrylamide gel electrophoresis. The labeled core protein was 
visualized by autoradiography. The signals were quantified by 
densitometry analysis and expressed as percentage of the 
respective control cells to indicate the IL-6 effect on capsid 
stability. Results shown are representative of three inde-
pendent experiments.Journal of Biomedical Science 2009, 16:41 http://www.jbiomedsci.com/content/16/1/41
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Figure 6 
The antiviral effect of IL-6 on HBV replication is not mediated through induction of IFNs. (A) Confluent
1.3ES2 cells were treated with or without 20 ng/ml of IL-6 for 2 day (day2) or 4 days (day4). Total RNA of each
sample was extracted for the detection of IFN-2b, IFN-, IFN- and -actin by RT-PCR analysis. Cells were transfected with
20 g poly (I:C) for 6 h and served as the positive control for the induction of IFN-2b and IFN- simultaneously. Plasmid con-
taining IFN- gene was served as the positive control for the detection of IFN-. (B) Confluent 1.3ES2 cells were treated with
or without 20 ng/ml of IL-6 for 1 day (day1), 3 days (day3) or 6 days (day6). Total RNA of each sample was extracted for the
detection of GBP-1 (target gene for IFN-), MxA (target gene for type I IFN) and GAPDH by RT-PCR analysis. Cells were
treated with IFN- or IFN- for 18 h and served as the positive control for the induction of GBP-1 and MxA genes. (C) Con-
fluent 1.3ES2 cells were treated with various concentration of IL-6 or IFN- for 4 days in the absence or presence of anti-IFN-
 polyclonal antibody (400 U/ml). The level of HBV genome-containing nucleocapsids was measured as mentioned above. The
expression level of -actin was used as an internal control for sample loading.
form DNA, but not cccDNA, were denatured into single-
stranded DNA after melting at 85°C for 5 min. Subse-
quent EcoRI digestion linearized the intact cccDNA and
the DNA's mobility was shifted from cccDNA to the posi-
tion of the duplex-linear form DNA (3.2 kb). Southern
blot analysis demonstrated that the amount of HBV
cccDNA was significant reduced in the presence of IL-6, as
compared with the mock-control cells (Fig. 7). However,
the amount of cccDNA after 6 days of IL-6 treatment was
similar to the pre-existing level of cccDNA of 1.3ES2 cellsJournal of Biomedical Science 2009, 16:41 http://www.jbiomedsci.com/content/16/1/41
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IL-6 decreases the formation of HBV cccDNA Figure 7
IL-6 decreases the formation of HBV cccDNA. Conflu-
ent cells (day0) were treated with or without 20 ng/ml of IL-
6 for 4 days (day4) or 6 days (day6) and subjected to Hirt 
extraction to prepare HBV cccDNA. The Hirt extract was 
thermally denatured at 85°C for 5 min, digested with EcoRI 
and analyzed by Southern blotting using an HBV-specific 
probe. Bands corresponding to HBV cccDNA and HBV sin-
gle-stranded DNA (SS) are indicated. The signals were quan-
tified by densitometry analysis and expressed as percentage 
of the control cells to indicate the IL-6 effect on the accumu-
lation of HBV cccDNA.
at day 0. These results indicated that IL-6 was able to effec-
tively prevent the accumulation of cccDNA, but was not
able to decrease the existing pool of cccDNA.
Discussion
In this study, we found that IL-6 suppressed HBV replica-
tion in an HBV-replicating cell line. The inhibitory effect
was not a result of cell apoptosis since IL-6 treatment
increased cell proliferation. We also demonstrated that IL-
6 exerted its inhibitory effect through a combination of
two different mechanisms which included a moderate
reduction of HBV transcripts/core protein coordinately
and a marked decrease in the level of HBV genome-con-
taining nucleocapsids. Furthermore, IL-6 also prevents the
accumulation of HBV cccDNA. IL-6 has recently been
found to suppress HCV RNA replication and protein
expression in liver cells [25]. This result coincides with our
findings and supports the suggestion that IL-6 is an anti-
viral cytokine during the progression of chronic hepatitis.
The pathogenesis of HBV-induced liver diseases involves
complicated mechanisms related to viral replication and
the body's immune responses against HBV infection [26],
including HBV-specific cell-mediated immunity (CMI)
and inflammatory cytokines. The CMI responses are
essential for the resolution of HBV infection, but several
studies have indicated that cytokines are involved in the
noncytopathic suppression of virus replication [5]. Of sig-
nificance to the present study is that the levels of many
cytokines (including IL-18, IFNs, TNF-, IL-4 and TGF-1)
are elevated during hepatitis progression, and have been
demonstrated to exhibit antiviral activity in both trans-
genic mice and cell culture systems [8-10,12,13,24]. Inter-
estingly, the levels of serum IL-6 were reported to
represent the best marker of HBV-related clinical progres-
sion as compared with IL-10, IL-12 and IFN- [20]. The
inhibitory mechanisms of the cytokines can be generally
divided into two major classes. The first class, which
includes IL-4 and TGF-1, suppresses viral gene expres-
sion and subsequently blocks HBV replication. IL-4 sup-
presses HBV replication through down-regulation of C/
EBP, while TGF-1 reduces HBV replication through
transcriptional inhibition of pregenomic RNA. Cytokines
of the second class exert their antiviral effect by either
destabilizing viral genome-containing capsids or prevent-
ing their assembly. Types I and II IFN activate hepatocel-
lular processes, which prevent the formation of viral
genome-containing capsids and subsequently inhibit
HBV replication [10], whereas the inhibitory effect of
TNF- involves the destabilization of viral nucleocapsids
[27]. In this study, we demonstrated that IL-6 exerted its
antiviral effect through a moderate reduction of viral tran-
scripts similar to IL-4 and TGF-1 and a more dramatic
reduction of viral genome-containing nucleocapsids.
These results indicate that the inhibitory mechanism of IL-
6 in HBV replication is a combination of both classes of
cytokines.
The IL-6 effect on the reduction of HBV genome-contain-
ing nucleocapsids may be similar to interferons and medi-
ated through the prevention of the formation of genome-
containing nucleocapsids since there is no evidence of the
disruption of capsid integrity after IL-6 treatment. The
expression levels of IFNs and IFN target genes were not
induced during the IL-6 treatment. These results indicate
that IL-6 induced suppression of HBV replication is not
mediated through the induction of IFNs.
The formation of HBV genome-containing nucleocapsids
involves very complicated processes. These processes
include dimerization of core protein and multimer associ-
ation, binding of RNA polymerase to  structure of prege-
nomic RNA (pgRNA) and packaging of pgRNA, viral
polymerase and cellular factors such as heat shock pro-
teins into capsids [28,29]. The IL-6 effect on the preven-
tion of the formation of viral genome-containing
nucleocapsids could occur at any step of these processes.Publish with BioMed Central    and   every 
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Similar to the inhibitory effect of IFNs, the exact mecha-
nism involved in the antiviral effect of IL-6 remains to be
further investigated.
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